Physician profile
David Shaw
NPI 1669454500
$16,578.21
in general payments reported to CMS, 2019-2025
55 companies · $2,717 in 2025
The $2,717 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,878 · 2020: $2,012 · 2021: $2,804 · 2022: $2,646 · 2023: $2,438 · 2024: $2,082 · 2025: $2,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,224 · Entertainment: $13.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,223.96 |
| Entertainment | $13.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,908.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,690.15 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,663.99 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $1,566.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,108.69 | 2019-2025 | |
| Novo Nordisk INC | $883.45 | 2019-2025 | Rybelsus, Ozempic |
| Amgen INC. | $706.64 | 2019-2024 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $696.37 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $517.73 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.49 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Dexcom, INC. | $454.67 | 2020-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $449.13 | 2019-2025 | Xifaxan, Ibschek |
| Merck Sharp & Dohme LLC | $434.67 | 2020-2023 | Verquvo, Belsomra, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $359.52 | 2019-2024 | Xarelto, Spravato |
| Otsuka America Pharmaceutical, INC. | $234.19 | 2020-2025 | Rexulti |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.